Compare McCormick & Company, Incorporated (MKC) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs State Street SPDR S&P Biotech ETF — how do they compare? McCormick & Company, Incorporated trades at $52.97 (market cap $14.24B), while State Street SPDR S&P Biotech ETF trades at $159.7. The key difference: McCormick & Company, Incorporated pays a 3.62% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, McCormick & Company, Incorporated nearer its low. Which is the better fit depends on your goals.
| MKC | XBI | |
|---|---|---|
Market Cap | $14.24B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $72.26 | $164.28 |
52-Week Low | $45.60 | $88.79 |
Enterprise Value | $18.84B | — |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $52.93, down 0.38% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion merger with Unilever's food business, expected to complete in 2027, driving positive analyst sentiment and a consensus price target of $59.67.
The outlook for MKC is positive, supported by margin expansion, strategic acquisitions, and the potential upside from the Unilever deal. Key risks include integration challenges from the merger, soft consumer volumes, and competitive pressures. With a 4% dividend yield and 35% upside to some price targets, the stock presents a compelling opportunity for long-term investors despite near-term volatility.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
